Cargando…

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis

BACKGROUND: Crizanlizumab was approved by the United States Food and Drug Administration agency in 2019 for decreasing vaso-occlusive events (VOEs) in sickle cell disease (SCD). Data regarding the use of crizanlizumab in the real-world setting are limited. Our goal was to identify patterns of crizan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheplowitz, Halle, Block, Shanna, Groesbeck, Jessica, Sacknoff, Stefanie, Nguyen, Anthony L., Gopal, Srila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332863/ https://www.ncbi.nlm.nih.gov/pubmed/37435415 http://dx.doi.org/10.14740/jh1127

Ejemplares similares

P1441: REAL-WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB-TREATED PATIENTS WITH SICKLE CELL DISEASE.
por: Summers, Kim, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A, et al.
Publicado: (2022)

P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A. C., et al.
Publicado: (2022)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
por: Heeney, M, et al.
Publicado: (2022)

Crizanlizumab: A CRITICAL Drug During a CRITICAL Time?
por: Gue, Ying X., et al.
Publicado: (2021)

Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review
por: Dick, Maurice H, et al.
Publicado: (2022)

O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: A., SILVA-PINTO, et al.
Publicado: (2022)

Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series
por: Idowu, Modupe, et al.
Publicado: (2023)

PB2213: EFFECTIVENESS OF CRIZANLIZUMAB IN REDUCING VASO-OCCLUSIVE CRISIS IN PATIENTS WITH SICKLE CELL DISEASE IN BRAZIL: STUDY PROTOCOL FOR AN OBSERVATIONAL, RETROSPECTIVE, MULTICENTER, NATIONAL STUDY
por: Bueno, C., et al.
Publicado: (2022)

Impact of Crizanlizumab on Acute Medical Care Utilization in the Height of the COVID-19 Pandemic
por: Rao, Shivani, et al.
Publicado: (2021)

Real-world outcomes of stem cell transplantation for severe aplastic anemia: A single-center experience in Northern India
por: Choudhury, Dharma, et al.
Publicado: (2020)

Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report
por: Alshurafa, Awni, et al.
Publicado: (2022)

S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
por: Heeney1, Matthew, et al.
Publicado: (2023)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
por: Baruwa Etti, A., et al.
Publicado: (2023)

S108: A SYSTEMATIC POST-MARKETING (PM) REVIEW OF RARE INFUSION-RELATED REACTIONS (IRRS) PRESENTING AS PAIN EVENTS DURING OR AFTER CRIZANLIZUMAB INFUSION IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
por: Kanter, J, et al.
Publicado: (2022)

Real-World Analysis of Therapeutic Outcome in Type 1 Diabetes Mellitus at a Tertiary Care Center
por: Kietaibl, Antonia, et al.
Publicado: (2022)

Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial
por: Leucker, Thorsten M., et al.
Publicado: (2021)

5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB
por: Kanter, J., et al.
Publicado: (2023)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

Pretibial hematomas – A real-world single-center study
por: Seppälä, T., et al.
Publicado: (2022)

Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
por: Jaksa, Ashley, et al.
Publicado: (2023)

Levels of inflammatory markers are differentially expressed in sickle cell anemia and sickle cell trait
por: Gomes, Ingrid Cristiane Pereira, et al.
Publicado: (2023)

Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction
por: Bickel, Fabian, et al.
Publicado: (2022)

Refining eligibility criteria of unit selection for myeloablative cord blood transplantation in acute leukemia: Real‐world experience of a referral center
por: Sun, Zimin, et al.
Publicado: (2023)

Carotid Artery Stenting: A Single Center “Real World” Experience
por: Krasniqi, Nazmi, et al.
Publicado: (2012)

Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
por: De Franceschi, Lucia, et al.
Publicado: (2022)

Severity and burden of sickle cell disease in France: a nationwide real-world study
por: Brousse, Valentine, et al.
Publicado: (2023)

Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence
por: Cançado, Rodolfo Delfini, et al.
Publicado: (2023)

Tackling sickle cell crisis in Nigeria: the need for newer therapeutic solutions in sickle cell crisis management – short communication
por: Mary Nnagha, Ekene, et al.
Publicado: (2023)

P1497: BURDEN OF SICKLE CELL DISEASE: RESULTS FROM THE REAL WORLD ASSESSMENT SURVEY FOR SICKLE CELL DISEASE IN SAUDI (ROARS)
por: Jastaniah, W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ls1s295hg0tf7iv1il1uk5b4oc